CA3240617A1 - Ig-like fusion proteins and use thereof - Google Patents

Ig-like fusion proteins and use thereof Download PDF

Info

Publication number
CA3240617A1
CA3240617A1 CA3240617A CA3240617A CA3240617A1 CA 3240617 A1 CA3240617 A1 CA 3240617A1 CA 3240617 A CA3240617 A CA 3240617A CA 3240617 A CA3240617 A CA 3240617A CA 3240617 A1 CA3240617 A1 CA 3240617A1
Authority
CA
Canada
Prior art keywords
fragment
domain
seq
polypeptide
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3240617A
Other languages
English (en)
French (fr)
Inventor
Kfir Oved
Galit Denkberg
Sharon REEF
Yelena PINZUR
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Canopy Immuno Therapeutics Ltd
Original Assignee
Canopy Immuno Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canopy Immuno Therapeutics Ltd filed Critical Canopy Immuno Therapeutics Ltd
Publication of CA3240617A1 publication Critical patent/CA3240617A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3240617A 2021-12-13 2022-12-13 Ig-like fusion proteins and use thereof Pending CA3240617A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163288782P 2021-12-13 2021-12-13
US63/288,782 2021-12-13
PCT/IL2022/051321 WO2023112028A1 (en) 2021-12-13 2022-12-13 Ig-like fusion proteins and use thereof

Publications (1)

Publication Number Publication Date
CA3240617A1 true CA3240617A1 (en) 2023-06-22

Family

ID=86774007

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3240617A Pending CA3240617A1 (en) 2021-12-13 2022-12-13 Ig-like fusion proteins and use thereof

Country Status (6)

Country Link
US (1) US20250059255A1 (https=)
EP (1) EP4447993A4 (https=)
JP (1) JP2024547218A (https=)
CN (1) CN118678964A (https=)
CA (1) CA3240617A1 (https=)
WO (1) WO2023112028A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120500348A (zh) * 2022-12-13 2025-08-15 卡努佩免疫治疗公司 用于治疗重症肌无力的Ig样融合蛋白
WO2025030000A1 (en) * 2023-08-01 2025-02-06 Merida Biosciences, Inc. Molecules for controlling autoimmune response
AU2024318666A1 (en) * 2023-08-01 2026-01-22 Merida Biosciences, Inc. Molecules for controlling autoimmune response
WO2025126210A1 (en) * 2023-12-13 2025-06-19 Canopy Immuno-Therapeutics Ltd. Ig-like fusion proteins for treating musk myasthenia gravis
WO2025126216A1 (en) * 2023-12-13 2025-06-19 Canopy Immuno-Therapeutics Ltd. Improved acetylcholine receptor molecules and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100719020B1 (ko) * 2005-09-28 2007-05-17 광주과학기술원 재조합 아세틸콜린 수용체 폴리펩티드, 폴리펩티드 유도체및 이를 유효성분으로 포함하는 중증근무력증 치료제
JP4857396B1 (ja) * 2011-04-13 2012-01-18 日本製薬株式会社 融合蛋白質
WO2016044137A2 (en) * 2014-09-15 2016-03-24 The Trustees Of The University Of Pennsylvania Acetylcholine receptor-specific immunosuppressive compositions and methods of treatment of myasthenia gravis

Also Published As

Publication number Publication date
JP2024547218A (ja) 2024-12-26
WO2023112028A1 (en) 2023-06-22
EP4447993A1 (en) 2024-10-23
EP4447993A4 (en) 2026-04-01
US20250059255A1 (en) 2025-02-20
CN118678964A (zh) 2024-09-20

Similar Documents

Publication Publication Date Title
US20250059255A1 (en) Ig-like fusion proteins and use thereof
US12269885B2 (en) Anti-PD-L1/VEGF bifunctional antibody and use thereof
KR101637502B1 (ko) 치료용 개 면역글로불린 및 이를 이용하는 방법
KR20230029622A (ko) April 및 baff 억제 면역조절 단백질 및 사용 방법
NO321707B1 (no) Isolert DNA som koder for et TRAIL-polypeptid og et opploselig TRAIL-polypeptid, ekspresjonsvektor, fremgangsmate for fremstilling av et TRAIL-polypeptid, isolert DNA som koder for et fusjonsprotein, fremgangsmate for fremstilling av en TRAIL-oligomer, antistoff som binder et TRAIL-polypeptid, renset TRAIL-polypeptid og opploselig TRAIL-polypeptid, oligomer, farmasoytisk preparat, farmasoytisk preparat for bruk som et medikament, farmasoytisk preparat for anvendelse ved indusering av apoptose hos malceller samt anvendelse av et TRAIL-polypeptid ved fremstilling av et medikament.
AU2017357944A1 (en) Activin receptor type IIa variants and methods of use thereof
US20180194847A1 (en) Cd154 binding polypeptide and use thereof
CA3026652A1 (en) Anti-tnfrsf25 antibodies
US20140178388A1 (en) Multivalent antibody fragments and trimerized complexes thereof
US20250376502A1 (en) Ig-like fusion proteins for treating graves disease
KR20250166188A (ko) Tnfr2 결합 폴리펩타이드 및 이의 용도의 방법
WO2024127398A1 (en) Ig-like fusion proteins for treating myasthenia gravis
WO2023143547A1 (zh) 抗cd28抗体及其应用
EP2377888A1 (en) Fusion protein
WO2025126210A1 (en) Ig-like fusion proteins for treating musk myasthenia gravis
WO2025126216A1 (en) Improved acetylcholine receptor molecules and use thereof
KR20230052279A (ko) 비-천연 발생 변형 fc 수용체에 특이적으로 결합하는 igg의 인간 비-천연 발생 변형 fc 영역
CN109422814A (zh) 一种抗La/SSB嵌合体抗原修饰的NK细胞、其制备方法及其应用
EP4709746A1 (en) Ig-like fusion proteins for treating membranous nephropathy
WO2024189620A1 (en) Ig-like fusion proteins for treating pemphigus vulgaris and foliaceus
WO2024231931A1 (en) Ig-like fusion proteins for treating immune thrombocytopenia
JP2025525941A (ja) ＥＧＦＲｖＩＩＩを標的とする抗体および細胞免疫治療におけるその使用
WO2025126202A1 (en) P32-specific antibodies and car t cells for the treatment of p32 expressing tumors
CA3235433A1 (en) Dual function antigen binding molecules
WO2024163723A9 (en) Molecules that bind to follistatin polypeptides

Legal Events

Date Code Title Description
P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-P146 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: BSL VERIFIED - NO DEFECTS

Effective date: 20240911

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241203

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241203

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241203

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251204

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251204